BioCentury
ARTICLE | Deals

Building on 2018 deal, Pfizer developing COVID-19 vaccine with BioNTech

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

March 14, 2020 12:05 AM UTC
Updated on Mar 24, 2020 at 10:54 PM UTC

Pfizer is working with BioNTech to develop an mRNA-based COVID-19 vaccine, the pharma disclosed Friday while outlining its plan to fight COVID-19. The news sent BioNTech’s stock up $2.38 to $30.93 Friday.

The companies partnered in 2018 to use mRNA technology from BioNTech SE (NASDAQ:BNTX) to develop flu vaccines (see “BioNTech, Pfizer Sic mRNA on the Flu”)...

BCIQ Company Profiles

BioNTech SE

Pfizer Inc.